1. Home
  2. IAG vs RDY Comparison

IAG vs RDY Comparison

Compare IAG & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iamgold Corporation

IAG

Iamgold Corporation

HOLD

Current Price

$18.06

Market Cap

13.1B

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.37

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAG
RDY
Founded
1990
1984
Country
Canada
India
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1B
11.6B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
IAG
RDY
Price
$18.06
$13.37
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$17.25
$16.90
AVG Volume (30 Days)
8.8M
1.6M
Earning Date
02-17-2026
01-20-2026
Dividend Yield
N/A
0.54%
EPS Growth
N/A
5.58
EPS
0.59
0.76
Revenue
$2,234,600,000.00
$3,848,694,754.00
Revenue This Year
$66.01
$6.12
Revenue Next Year
$32.64
$2.58
P/E Ratio
$35.46
$17.53
Revenue Growth
52.98
11.09
52 Week Low
$5.02
$12.26
52 Week High
$22.43
$16.17

Technical Indicators

Market Signals
Indicator
IAG
RDY
Relative Strength Index (RSI) 48.46 44.44
Support Level $20.15 $13.13
Resistance Level $22.43 $13.85
Average True Range (ATR) 1.05 0.22
MACD 0.03 0.02
Stochastic Oscillator 24.78 48.46

Price Performance

Historical Comparison
IAG
RDY

About IAG Iamgold Corporation

Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: